EA199900261A1 - Генная терапия застойной сердечной недостаточности - Google Patents
Генная терапия застойной сердечной недостаточностиInfo
- Publication number
- EA199900261A1 EA199900261A1 EA199900261A EA199900261A EA199900261A1 EA 199900261 A1 EA199900261 A1 EA 199900261A1 EA 199900261 A EA199900261 A EA 199900261A EA 199900261 A EA199900261 A EA 199900261A EA 199900261 A1 EA199900261 A1 EA 199900261A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- heart failure
- gene therapy
- stable heart
- present
- hearts
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 238000001415 gene therapy Methods 0.000 title 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Настоящее изобретение относится к способам и композициям по усилению кардиальной функции в сердцах млекопитающих путем введения трансгенов, которые повышают β-адренергический ответ в миокарде. Настоящее изобретение может, поэтому, использоваться для лечения заболевания сердца, особенно застойной сердечной недостаточности.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70866196A | 1996-09-05 | 1996-09-05 | |
US4893397P | 1997-06-16 | 1997-06-16 | |
PCT/US1997/015610 WO1998010085A2 (en) | 1996-09-05 | 1997-09-05 | Gene therapy for congestive heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
EA199900261A1 true EA199900261A1 (ru) | 1999-10-28 |
Family
ID=26726691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199900261A EA199900261A1 (ru) | 1996-09-05 | 1997-09-05 | Генная терапия застойной сердечной недостаточности |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0934422B1 (ru) |
JP (1) | JP2002514908A (ru) |
CN (1) | CN1234835A (ru) |
AT (1) | ATE347606T1 (ru) |
AU (1) | AU741931B2 (ru) |
CA (1) | CA2262406C (ru) |
DE (1) | DE69737062T2 (ru) |
EA (1) | EA199900261A1 (ru) |
WO (1) | WO1998010085A2 (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1136920C (zh) | 1995-02-28 | 2004-02-04 | 加利福尼亚大学董事会 | 基因转移介导的血管形成疗法 |
US6321109B2 (en) | 1996-02-15 | 2001-11-20 | Biosense, Inc. | Catheter based surgery |
US6465237B1 (en) | 1997-07-01 | 2002-10-15 | Millennium Pharmaceuticals, Inc. | Cloning and characterization of a human adenylyl cyclase |
JP2002514926A (ja) * | 1997-07-01 | 2002-05-21 | シーオーアール セラピューティクス インコーポレイテッド | ヒト・アデニル酸シクラーゼのクローニングおよび特性評価 |
ES2293473T3 (es) | 1998-02-05 | 2008-03-16 | Biosense Webster, Inc. | Administracion intracardiaca de farmaco. |
WO1999062940A2 (en) * | 1998-05-30 | 1999-12-09 | Collateral Therapeutics, Inc. | Methods of altering cardiac cell phenotype |
IT1308613B1 (it) | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
EP1255822A2 (en) | 1999-12-27 | 2002-11-13 | The Regents Of The University Of California | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
US20070265221A1 (en) * | 2006-05-09 | 2007-11-15 | Weiss Robert G | Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure |
JP2011503207A (ja) * | 2007-11-16 | 2011-01-27 | サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション | 循環系細胞におけるpim−1活性を操作するための組成物および方法 |
EP2244740A1 (en) | 2008-02-19 | 2010-11-03 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334521A (en) * | 1991-11-18 | 1994-08-02 | American Cyanamid Company | Cloning and characterization of a cardiac adenylyl cyclase |
US6034071A (en) * | 1994-09-16 | 2000-03-07 | Iyengar; Srinivas Ravi V. | Mutant activated GS α and adenylyl cyclase 2 for use as therapeutic agents |
WO1997016169A1 (en) * | 1995-11-01 | 1997-05-09 | Chiron Corporation | Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
WO1997017937A2 (de) * | 1995-11-17 | 1997-05-22 | Franz Wolfgang M | Gentherapeutisches nukleinsäurekonstrukt, seine herstellung und verwendung zur behandlung von herzerkrankungen |
-
1997
- 1997-09-05 AT AT97940830T patent/ATE347606T1/de not_active IP Right Cessation
- 1997-09-05 CA CA2262406A patent/CA2262406C/en not_active Expired - Lifetime
- 1997-09-05 DE DE69737062T patent/DE69737062T2/de not_active Expired - Lifetime
- 1997-09-05 JP JP51291598A patent/JP2002514908A/ja not_active Ceased
- 1997-09-05 AU AU42519/97A patent/AU741931B2/en not_active Expired
- 1997-09-05 EP EP97940830A patent/EP0934422B1/en not_active Expired - Lifetime
- 1997-09-05 EA EA199900261A patent/EA199900261A1/ru unknown
- 1997-09-05 CN CN97197695A patent/CN1234835A/zh active Pending
- 1997-09-05 WO PCT/US1997/015610 patent/WO1998010085A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO1998010085A3 (en) | 1998-05-14 |
CA2262406A1 (en) | 1998-03-12 |
WO1998010085A2 (en) | 1998-03-12 |
ATE347606T1 (de) | 2006-12-15 |
EP0934422A2 (en) | 1999-08-11 |
DE69737062T2 (de) | 2007-07-12 |
EP0934422B1 (en) | 2006-12-06 |
CA2262406C (en) | 2010-12-07 |
CN1234835A (zh) | 1999-11-10 |
JP2002514908A (ja) | 2002-05-21 |
AU741931B2 (en) | 2001-12-13 |
AU4251997A (en) | 1998-03-26 |
DE69737062D1 (de) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200200097A1 (ru) | Имидазоимидазолы и триазолы в качестве противовоспалительных агентов | |
EA199900261A1 (ru) | Генная терапия застойной сердечной недостаточности | |
DE60021199D1 (de) | Hemmung der expression von genen mittels dsrna | |
EA199800667A1 (ru) | Новые фенантридины | |
EA199900936A1 (ru) | Фунгицидные трифторметилалкиламинотриазолопиримидины | |
DE69332030D1 (de) | Herstellung von heterologen proteinen in filamentösen fungi | |
EA200100589A1 (ru) | Азабициклоалканы как модуляторы ccr5 | |
EA200300171A1 (ru) | Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения | |
EA200800375A1 (ru) | Соединения и способы ингибирования экспрессии vcam-1 | |
EA199900462A1 (ru) | Способы и композиции для стимуляции роста невритов, использующие соединения с афинностью к fkbp12 в комбинации с нейротрофическими факторами | |
EA200500856A1 (ru) | Новые химические соединения | |
EA200000926A1 (ru) | Экспрессия генов биосинтеза трегалозы в растениях | |
ATE160178T1 (de) | Verfahren und diagnostische kits unter verwendung von säuger-stresspromotoren zur bestimmung der toxizität einer verbindung | |
EA200000239A1 (ru) | Стимуляторы секреции гормона роста | |
PT988301E (pt) | Acetais ciclicos de imidazolilo | |
EA199900421A1 (ru) | Бензонафтиридины в качестве бронхиальных терапевтических средств | |
DK545584A (da) | Enzym-resistente immonumodulatoriske peptider | |
BR9909677A (pt) | Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas | |
EA200100264A1 (ru) | Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly | |
ES2074280T3 (es) | Metodo para modificar el tropismo de celula, tejido o huesped de un microorganismo, microorganismos recombinantes obtenidos de este modo y su uso en medicina y medicina veterinaria. | |
DE3767287D1 (de) | Potenzierung von prazosin. | |
WO2001048164A3 (en) | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure | |
DK540586D0 (da) | Cardiotonisk virksomme thiazoloner | |
EA200001097A1 (ru) | Стабильные композиции, содержащие левозимендан и альгиновую кислоту | |
ATE233321T1 (de) | Verbesserungen in der herstellung von proteinen in wirtszellen |